Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
Pharmaceutical Investing Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Freegold Reports Final 2024 Drilling Results from Golden Summit Continuing to Confirm Higher Grade Potential
Group Eleven Intersects 12.0m of 2.30% Cu and 560 g/t Ag, Including 6.4m of 3.72% Cu and 838 g/t Ag, Demonstrating High-Grade Copper and Silver Potential at Ballywire
